Regorafenib (Standard)

CAT:
804-HY-10331R-01
Size:
5 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Regorafenib (Standard) - image 1

Regorafenib (Standard)

  • Description :

    Regorafenib (Standard) is the analytical standard of Regorafenib. This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].
  • Product Name Alternative :

    BAY 73-4506 (Standard)
  • UNSPSC :

    12352005
  • Target :

    Autophagy; c-Kit; FGFR; PDGFR; Raf; Reference Standards; RET; Tie; VEGFR
  • Type :

    Reference Standards
  • Related Pathways :

    Autophagy; MAPK/ERK Pathway; Others; Protein Tyrosine Kinase/RTK
  • Field of Research :

    Cancer
  • Assay Protocol :

    https://www.medchemexpress.com/regorafenib-standard.html
  • Smiles :

    O=C(NC1=CC=C(C(C(F)(F)F)=C1)Cl)NC2=CC=C(OC3=CC(C(NC)=O)=NC=C3)C=C2F
  • Molecular Formula :

    C21H15ClF4N4O3
  • Molecular Weight :

    482.82
  • References & Citations :

    [1]Wilhelm SM, et al. Regorafenib (BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129 (1), 245-255.|[2]Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2 (1), 39-49.|[3]Carr BI, et al. Fluoro-Bay 43-9006 (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228 (2), 292-297.|[4]Wagner J, et al. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms. J Exp Clin Cancer Res. 2018 Jan 22;37 (1) :11.|[5]Matsuoka K, et al. Effective Sequential Combined Chemotherapy with Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018 Sep 25;19 (10) . pii: E2915.
  • Shipping Conditions :

    Room temperature
  • Scientific Category :

    Reference Standards
  • CAS Number :

    [755037-03-7]